References
1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 2002;359:1451-9. DOI: 10.1016/S0140-6736(02)08512-4
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2005;353:2462-76. DOI: 10.1056/NEJMoa050516
3. Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther 2018;18:633-40. DOI: 10.1080/14712598.2018.1469620
4. Gonczi L, Gecse KB, Vegh Z, et al. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab after One Year in a Prospective Nationwide Cohort. Inflamm Bowel Dis 2017;23:1908-15. DOI: 10.1097/MIB.0000000000001237
5. Papamichael K, Stappen T Van, Jairath V, et al. Review article: Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;42:1158-69. DOI: 10.1111/apt.13402
6. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis 2013;72:1613-20. DOI: 10.1136/annrheumdis-2012-203090
7. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54. DOI: 10.1136/annrheumdis-2015-208783
8. Arguëlles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol 2017;29:1290-5. DOI: 10.1097/MEG.0000000000000953
9. Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45:1043-57. DOI: 10.1111/apt.13990
10. Danese S, Fiorino G, Raine T, et al. ECCO Position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohn’s Colitis 2017;1:26-34. DOI: 10.1093/ecco-jcc/jjw198
11. Bronswijk M, Moens A, Lenfant M, et al. Evaluating Efficacy, Safety, and Pharmacokinetics after Switching from Infliximab Originator to Biosimilar CT-P13: Experience from a Large Tertiary Referral Center. Inflamm Bowel Dis 2020;26(4):628-34. DOI: 10.1093/ibd/izz167
12. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16. DOI: 10.1016/S0140-6736(17)30068-5
13. Smits LJT, Grelack A, Derikx LAAP, et al. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3117-22. DOI: 10.1007/s10620-017-4661-4
14. Smits LJT, Esch AAJ Van, Derikx LAAP, et al. Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: Two-year follow-up of a prospective observational cohort study. Inflamm. Bowel Dis 2019;25:172-9. DOI: 10.1093/ibd/izy227
15. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 2019;393:1699-707. DOI: 10.1016/S0140-6736(18)32196-2
16. Berends SE, Strik AS, Selm JC Van, et al. Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients with Crohn’s Disease. Ther. Drug Monit 2018;40:202-11. DOI: 10.1097/FTD.0000000000000494
17. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn’s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials. Clin Ther 2011;33:946-64. DOI: 10.1016/j.clinthera.2011.06.002
18. Mitrev N, Casteele N Vande, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. DOI: 10.1111/apt.14368
19. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatology Venereol 2016;30:1148-58. DOI: 10.1111/jdv.13611
20. Smits LJT, Derikx LAAP, Jong DJ de, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study. J Crohn’s Colitis 2016;10:1287-93. DOI: 10.1093/ecco-jcc/jjw087
21. Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther 2018;20:1-13. DOI: 10.1186/s13075-018-1646-4
22. Santacana E, Rodríguez-Alonso L, Padullés A, et al. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. 2020; Ther Drug Monit 2020;42:102-10. DOI: 10.1097/FTD.0000000000000669
23. Gil Candel M, Gascón Cánovas JJ, Espín RG, et al. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enf Dig 2020;112:590-7. DOI: 10.17235/reed.2020.6857/2020
24. Mitchell RA, Shuster C, Shahidi N, et al. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Can J Gastroenterol Hepatol 2016;2016:5203898. DOI: 10.1155/2016/5203898
25. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-68. DOI: 10.1016/j.cgh.2019.03.037
26. Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J. Crohn’s Colitis 2020;14:542-56. DOI: 10.1093/ecco-jcc/jjz162
27. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. DOI: 10.1007/s40259-017-0231-8
28. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014;34:1701-8. DOI: 10.1007/s00296-014-3032-0
29. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 2015;29:241-58. DOI: 10.1007/s40259-015-0134-5
30. Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-Inhibitors. Front Immunol 2020;11:1-13. DOI: 10.3389/fimmu.2020.00312
31. Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohns Colitis 2017;11:690-6. DOI: 10.1093/ecco-jcc/jjw216
32. Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther 2019;49:31-40. DOI: 10.1111/apt.14997
33. Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther 2019;2491-502. DOI: 10.2147/DDDT.S200147
34. Meyer A, Rudant J, Drouin J, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French equivalence study. Ann Intern Med 2019;170:99-107. DOI: 10.7326/M18-1512